EP0324762A1 - A granulate containing gamma linolenic acid, eicosapentaenoic acid and/or docosahexaenoic acid, the method for its manufacturing, its use in edible products, and a tablet containing it - Google Patents

A granulate containing gamma linolenic acid, eicosapentaenoic acid and/or docosahexaenoic acid, the method for its manufacturing, its use in edible products, and a tablet containing it

Info

Publication number
EP0324762A1
EP0324762A1 EP87906285A EP87906285A EP0324762A1 EP 0324762 A1 EP0324762 A1 EP 0324762A1 EP 87906285 A EP87906285 A EP 87906285A EP 87906285 A EP87906285 A EP 87906285A EP 0324762 A1 EP0324762 A1 EP 0324762A1
Authority
EP
European Patent Office
Prior art keywords
oil
granulate
acid
powder mixture
binder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP87906285A
Other languages
German (de)
French (fr)
Inventor
Jan Ingemar Vogeler
Nils-Erik Lennart Andersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Kabi Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia AB filed Critical Kabi Pharmacia AB
Publication of EP0324762A1 publication Critical patent/EP0324762A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/10—Shaping or working-up of animal feeding-stuffs by agglomeration; by granulation, e.g. making powders
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Definitions

  • the present invention relates to a granulate comprising an oil-powder mixture containing 2-75 % oil concentration of vegetable and/or marine 5 oils and a water-soluble carrier in combination with a solid pulverulent filler and a binder, and to the preparation of said granulate, use of said granulate especially for the preparation of tablets, as well as said tablets.
  • oils containing essential fatty acids are administrated in fluid form in bottles, containers or in soft or hard gelatin capsules. Particularly, this applies to oils containing 15 gamma linolenic acid (GLA), eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA).
  • GLA gamma linolenic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • the object of the present invention is to prepare a granulate, having a high content of fatty acids and co pressability properties especially l . suitable for the preparation of tablets for application in pharmacy, dietary supplements, food products and veterinary medicine.
  • Oils suitable for conversion to an oil powder mixture are vegetable oils and marine oils containing essential fatty acid, especially oils containing gamma linolenic acid (GLA), eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA).
  • GLA gamma linolenic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • oils suitable in mixed or unmixed form to be convertible to powder phase are vegetable oil such as black currant oil, borage oil, evening primrose oil, wheat germ oil (vitamin E), biosynthetic gamma linolenic acid oil and marine oils such as cod liver oil, salmon oil and shark liver oil.
  • Antioxidant e.g. vitamin E (alpha tocopherol) or combined alpha tocopherol and ascorbyl paImitate is added to the oil for protection against oxidation of the granulate in the manufacture and storing.
  • vitamin E alpha tocopherol
  • ascorbyl paImitate is added to the oil for protection against oxidation of the granulate in the manufacture and storing.
  • Carriers suitable for mixing with the oil to convert the oil to an oil powder are a defatted, water-soluble carrier alone or in combination.
  • Such carriers are proteins such as plant proteins e.g. soybean protein, animal proteins e.g. egg protein, milk protein, caseinate, polysaccharides such as starches e.g. corn starch, potato starch, amylopectin or cellulose.
  • an oil powder mixture free from animal substances can be prepared, which is important in manufacture of several products for allergical persons.
  • Suitable solid, pulverulent fillers for mixing with the oil-powder mixture are sugars or modified sugar products e.g. dextrose, lactose, fructose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin or cellulose.
  • sugars or modified sugar products e.g. dextrose, lactose, fructose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin or cellulose.
  • binders are such as unmodified or modified polysaccharide products, for instance cellulose polymers such as methyl cellulose; hydroxy propyl starch or acacia (Arab.gum).
  • additives are vitamins, enzymes, minerals, pollen products, ginseng products, flavouring agents and pharmaceutically active substances such as antibiotics, hormones, cortisones etc.
  • the preparation of the oil-powder mixture is in the following way:
  • the resulting mixture is then emulsified by means of a conventional high pressure homogenizer working at a pressure above 100 kg/cm (100-250 kg/cm ) ,
  • the emulsion formed is dried in a conventional spray-drier.
  • the emulsion out-coming from the nozzle meet warm air having a temperature about 200°C.
  • the powder formed in the spray-drier has a temperature of about 70°C, which can be lowered to room temperature (18-23°C) by passing a fluid-bed drier or similar device.
  • the oil-powder mixture has an average particle size of from 0,1 to l,5 ⁇ , at agglomeration the particle size increases.
  • the oil concentration of the oil-powder mixture may vary from 2 % to 75 % especially from 20 % to 75 % (w/w) preferably between 40 % to 75 % (w/w) depending on the amount of oil being added to the carrier solution (step iii above).
  • the preparation of the granulate of the present invention is performed in the following way:
  • the granulate obtained is then dried preferably by means of a microwave oven at a temperature between 20-50° C.
  • the dried granulate is then driven optionally together with additives through a sieve to desired size.
  • the granulate has preferably a particle size of from 0.5 to 3.0 mm
  • Drying of the granulate in microwave oven gives a very short drying time and prevent oxidation.
  • the granulate has suitable compressability properties to admit in the preparation of tablets, for human and animal use
  • the granulate can be mixed with other dry substances which means increased field of use, such as mixing in food products, in fodder, dietary supplement, pharmaceuticals etc.
  • compositions containing essential fatty acids in the form of dosage units for oral administration tablets are a preferred administration form.
  • Tablets are a preferred administration form compared to capsules since the dosage of the active substance can be varied within a much wider range compared with capsules. It is easy to make a tablet of a suitable size containing a sufficient amount of active substance. Several people prefer tablets to capsules owing to taste, design, easier to swallow etc.
  • Tablets of the present invention are especially suitable as chewing tablets or effervescent tablets.
  • the chewing tablets may also include vegetable fibres.
  • Incorporation of an acid/bicarbonate mixture e.g. a tartaric acid/sodium bicarbonate mixture, make the tablets effervescent on addition of water.
  • the tablets are prepared by pressing the granulate obtained optionally with addition of additives in a conventional tableting machine.
  • Additives can optionally be added in the preparation of the granulate and/or in preparation of the tablets.
  • Example 1 Oil-powder mixture, 50 % borage oil
  • Soybean protein was dissolved in water with vigorous stirring and heating to about 65°C. Borage oil containing antioxidant was heated to 65°-70°C and monoglyceride was added with vigorous stirring. The borage oil was mixed with the aqueous soybean protein solution with vigorous stirring. Then the mixture obtained was pumped to a conventional
  • the emulsion formed was then dried in a spray-drier, wherein the warm air has a temperature of 200°C.
  • the outcor ⁇ ing oil-powder mixture has a temperature of 70°C, which temperature was lowered to 20°C by passing a fluid-bed drier.
  • the resulting oil-powder mixture containing 50 % (w/w) oil has an average particle size of from 0,1 to 0,5 ⁇ .
  • Example 2 Oil-powder mixture, 50 % marine oil
  • the oil-powder mixture was prepared in the same way as described in Example 1.
  • the components were mixed to a granulate in the following way:
  • Methyl cellulose was mixed with water and the mixture was stored for 1-1,5 hours.
  • the borage oil-powder mixture as prepared in Example 1 was dry-mixed with dextrose and 5 mg methyl cellulose.
  • the methyl cellulose was added as a binder.
  • the dry-mixture was granulated with the water solution and the granulate obtained was dried in an oven during 24 hours or in a microwave oven, alternatively. After drying the granulate was driven through a sieve to desired size.
  • the granulate obtained may thereafter be pressed to a tablet in a conventional tableting machine with addition of a conventional binder
  • Cod liver oil-powder mixture (50 % oil) 350 mg
  • Example 7 GLA/EPA/DHA granulate
  • the ratio by weight of GLA oil-powder mixture and EPA/DHA oil-powder mixture in the combination granulate may vary.
  • Example 4 The granulate obtained in Example 4 was dry-mixed with the components pollen concentrate and lecithin and the binder Avicel with stirring then pressed to tablets in a conventional tableting machine.
  • Example 3 Average weight 715 mg The granulate obtained in Example 3 was mixed with the other components and formed to tablets in the same way as described in Example 8.
  • Example 4 The granulate obtained in Example 4 was mixed with the other components and formed to tablets in the same way as described in Example 8.
  • Granulate containing GLA and tablets containing GLA can be prepared from black currant oil, evening primrose oil, wheat germ oil or biosynthesis optionally with additives in the same way as described in Examples 3-5 and 7-10.
  • Granulate and tablets containing EPA/DHA can be prepared from marine oils optionally with additives in the same way as described in Examples 6-10.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Animal Husbandry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Est décrit un granulat comprenant un mélange huile-poudre contenant de 2 à 75 % d'huile végétale et/ou d'huile marine renfermant des acides gras essentiels sélectionnés parmi l'acide linolénique gamma (GLA), l'acide eicosapentaénoïque (EPA) et/ou l'acide docosahexaénoïque (DHA) et/ou d'autres huiles marines et un porteur hydrosoluble, en combinaison avec une charge pulvérulente solide et un liant. Sont également décrits des comprimés contenant ledit granulé ainsi que l'emploi dudit granulé et des comprimés en pharmacie, dans des compléments diététiques, des produits alimentaires et du fourrage.Is described a granulate comprising an oil-powder mixture containing from 2 to 75% of vegetable oil and / or marine oil containing essential fatty acids selected from gamma linolenic acid (GLA), eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA) and / or other marine oils and a water-soluble carrier, in combination with a solid powdery filler and a binder. Also described are tablets containing said granule as well as the use of said granule and tablets in pharmacies, in dietary supplements, food products and fodder.

Description

A granulate containing gamma linolenic acid, eicosapenta- enoic acid and/or docosa exaenoic acid, the method for its manufacturing, its use in edible products, and a tablet containing it.
Field of the invention
The present invention relates to a granulate comprising an oil-powder mixture containing 2-75 % oil concentration of vegetable and/or marine 5 oils and a water-soluble carrier in combination with a solid pulverulent filler and a binder, and to the preparation of said granulate, use of said granulate especially for the preparation of tablets, as well as said tablets.
10 Background of the invention
Currently available vegetable and marine oils containing essential fatty acids are administrated in fluid form in bottles, containers or in soft or hard gelatin capsules. Particularly, this applies to oils containing 15 gamma linolenic acid (GLA), eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA).
A great disadvantage with these oils in oil phase is that they can not be mixed with water-soluble substances. 20
A long-felt want is to prepare tablets comprising a- high content of the essential fatty acids GLA, and/or EPA/DHA, since tablets are an administration form easy of access. However, a lot of practical and technical problems have prevented the preparation of such tablets. 25 Surprisingly, the preparation of a granulate according to the present invention has been capable of solving these problems.
Description of the invention
30 The object of the present invention is to prepare a granulate, having a high content of fatty acids and co pressability properties especially l. suitable for the preparation of tablets for application in pharmacy, dietary supplements, food products and veterinary medicine. Oils suitable for conversion to an oil powder mixture are vegetable oils and marine oils containing essential fatty acid, especially oils containing gamma linolenic acid (GLA), eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA). Examples of oils suitable in mixed or unmixed form to be convertible to powder phase are vegetable oil such as black currant oil, borage oil, evening primrose oil, wheat germ oil (vitamin E), biosynthetic gamma linolenic acid oil and marine oils such as cod liver oil, salmon oil and shark liver oil.
Antioxidant e.g. vitamin E (alpha tocopherol) or combined alpha tocopherol and ascorbyl paImitate is added to the oil for protection against oxidation of the granulate in the manufacture and storing.
Carriers suitable for mixing with the oil to convert the oil to an oil powder are a defatted, water-soluble carrier alone or in combination. Such carriers are proteins such as plant proteins e.g. soybean protein, animal proteins e.g. egg protein, milk protein, caseinate, polysaccharides such as starches e.g. corn starch, potato starch, amylopectin or cellulose.
By a careful choice of vegetable carriers and vegetable oils, an oil powder mixture free from animal substances can be prepared, which is important in manufacture of several products for allergical persons.
Suitable solid, pulverulent fillers for mixing with the oil-powder mixture are sugars or modified sugar products e.g. dextrose, lactose, fructose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin or cellulose.
Conventional binders are such as unmodified or modified polysaccharide products, for instance cellulose polymers such as methyl cellulose; hydroxy propyl starch or acacia (Arab.gum).
Examples of additives are vitamins, enzymes, minerals, pollen products, ginseng products, flavouring agents and pharmaceutically active substances such as antibiotics, hormones, cortisones etc. The preparation of the oil-powder mixture is in the following way:
(i) heating the oil to e.g. 20-70°C depending on the oil used; optionally adding of an antioxidant a onoglyceride preferably 0,1-1,0 % (monoglyceride w/oil w) vegetable monoglyceride with vigorous stirring. The monoglyceride makes the homogenisation easier.
(ii) simultanously, a defatted carrier is dissolved in water with vigorous stirring and heating from e.g. 20°C to 65°C depending on the carrier used,
(iii) the mixture (i) containing the oil and the mixture (ii) containing the carrier in water solution are mixed with vigorous stirring,
(iv) the resulting mixture is then emulsified by means of a conventional high pressure homogenizer working at a pressure above 100 kg/cm (100-250 kg/cm ) , (v) the emulsion formed is dried in a conventional spray-drier. The emulsion out-coming from the nozzle meet warm air having a temperature about 200°C. The powder formed in the spray-drier has a temperature of about 70°C, which can be lowered to room temperature (18-23°C) by passing a fluid-bed drier or similar device.
The oil-powder mixture has an average particle size of from 0,1 to l,5μ, at agglomeration the particle size increases. The oil concentration of the oil-powder mixture may vary from 2 % to 75 % especially from 20 % to 75 % (w/w) preferably between 40 % to 75 % (w/w) depending on the amount of oil being added to the carrier solution (step iii above).
The preparation of the granulate of the present invention is performed in the following way:
(a) dry-mixing the oil-powder mixture, optionally containing an antioxidant, with a solid, pulverulent filler preferably dextrose, optionally adding of a diluent, with vigorous stirring, (b) simultanously, a conventional binder e.g. methyl cellulose, hydroxy propyl starch is dissolved in water with vigorous stirring,
(c) the dry-mixture (a) containing the oil-powder mixture and the filler and the mixture (b) containing the dissolved binder are mixed with vigorous stirring,
(d) the granulate obtained is then dried preferably by means of a microwave oven at a temperature between 20-50° C.
(e) the dried granulate is then driven optionally together with additives through a sieve to desired size.
The granulate has preferably a particle size of from 0.5 to 3.0 mm
Drying of the granulate in microwave oven gives a very short drying time and prevent oxidation.
The advantage of the granulate according to the invention is:
- that the granulate has a high content of oils
- that the granulate has suitable compressability properties to admit in the preparation of tablets, for human and animal use
- that the granulate can be mixed with other dry substances which means increased field of use, such as mixing in food products, in fodder, dietary supplement, pharmaceuticals etc.
In preparation of compositions containing essential fatty acids in the form of dosage units for oral administration tablets are a preferred administration form.
Tablets are a preferred administration form compared to capsules since the dosage of the active substance can be varied within a much wider range compared with capsules. It is easy to make a tablet of a suitable size containing a sufficient amount of active substance. Several people prefer tablets to capsules owing to taste, design, easier to swallow etc.
Tablets of the present invention are especially suitable as chewing tablets or effervescent tablets. The chewing tablets may also include vegetable fibres. Incorporation of an acid/bicarbonate mixture e.g. a tartaric acid/sodium bicarbonate mixture, make the tablets effervescent on addition of water.
The tablets are prepared by pressing the granulate obtained optionally with addition of additives in a conventional tableting machine.
Additives can optionally be added in the preparation of the granulate and/or in preparation of the tablets.
The invention will be illustrated by the following examples without being limited thereto.
Example 1 Oil-powder mixture, 50 % borage oil
Components
Soybean protein 480 kg Borage oil 480 kg
Water 1 760 1
Vegetable monoglyceride 1 kg
Soybean protein was dissolved in water with vigorous stirring and heating to about 65°C. Borage oil containing antioxidant was heated to 65°-70°C and monoglyceride was added with vigorous stirring. The borage oil was mixed with the aqueous soybean protein solution with vigorous stirring. Then the mixture obtained was pumped to a conventional
2 2 ho ogenizer working at a pressure above 100 kg/cm (100-250 kg/cm ) . The emulsion formed was then dried in a spray-drier, wherein the warm air has a temperature of 200°C. The outcorπing oil-powder mixture has a temperature of 70°C, which temperature was lowered to 20°C by passing a fluid-bed drier. The resulting oil-powder mixture containing 50 % (w/w) oil has an average particle size of from 0,1 to 0,5 μ.
Example 2 Oil-powder mixture, 50 % marine oil
Components
Soybean protein 480 kg
Marine o l 480 kg Water 1 760 1
Vegetable monoglyceride 3 kg
The oil-powder mixture was prepared in the same way as described in Example 1.
Example 3 GLA granulate
Components
Borage oil-powder mixture (50 % oil) 350 nig Dextrose (EMDEX ) 250 g
Methyl cellulose 15 mg
The components were mixed to a granulate in the following way:
10 mg Methyl cellulose was mixed with water and the mixture was stored for 1-1,5 hours. The borage oil-powder mixture as prepared in Example 1 was dry-mixed with dextrose and 5 mg methyl cellulose. The methyl cellulose was added as a binder. Thereafter the dry-mixture was granulated with the water solution and the granulate obtained was dried in an oven during 24 hours or in a microwave oven, alternatively. After drying the granulate was driven through a sieve to desired size. The granulate obtained may thereafter be pressed to a tablet in a conventional tableting machine with addition of a conventional binder
D such as a cellulose derivative e.g. Avice . Example 4 GLA granulate
Components
•< 5 Borage oil-powder mixture (50% oil) 350 mg Dextrose (EMDEXR) 250 mg
Hydroxy propyl starch 100 mg
The components were mixed to a granulate in the same way as described in 10 Example 3.
Example 5 GLA-Vitamin B6 granulate
Components 15
Borage oil-powder mixture (50% oil) 350 mg
Dextrose (EMDEXR) 250 mg
Hydroxy propyl starch 100 mg
Pyridoxine chloride 20 mg
20
The components were mixed to a granulate in the same way as described in Example 3.
Example 6 EPA/DHA granulate
25
Components
Cod liver oil-powder mixture (50 % oil) 350 mg
. Dextrose (EMDEXR) 250 mg
30 Methyl cellulose 15 mg
The components were mixed to a granulate in the same way as described in Example 3. Example 7 GLA/EPA/DHA granulate
Components
Borage oil-powder mixture (50 % oil) 250 mg
Shark liver oil-powder mixture (50 % oil) 150 mg
Dextrose 300 mg
Methyl cellulose 20 mg
The components were mixed to a granulate in the same way as described in Example 3.
The ratio by weight of GLA oil-powder mixture and EPA/DHA oil-powder mixture in the combination granulate may vary.
Example 8 GLA-pollen-lecithin tablet
Composition Tablet content
GLA granulate 700 mg
Pollen concentrate 95 mg Soybean lecithin 95 mg Cellulose (AvicelR) 100 mg
Average weight 990 mg
The granulate obtained in Example 4 was dry-mixed with the components pollen concentrate and lecithin and the binder Avicel with stirring then pressed to tablets in a conventional tableting machine.
Example 9 GLA-selenium tablet
Composition Tablet content
GLA granul te 615 mg Sodium seleπite 0.05 g
Cellulose (AvicelR) 100 mg
Average weight 715 mg The granulate obtained in Example 3 was mixed with the other components and formed to tablets in the same way as described in Example 8.
Example 10 GLA-vitamin B6 tablet
Composition Tablet content
GLA granulate 700 mg Pyridoxine chloride 20 mg Cellulose AvicelR 100 mg Fructose 40 mg Citric acid 12 mg Arom. lemon 28 mg
Average weight 900 mg
The granulate obtained in Example 4 was mixed with the other components and formed to tablets in the same way as described in Example 8.
Granulate containing GLA and tablets containing GLA can be prepared from black currant oil, evening primrose oil, wheat germ oil or biosynthesis optionally with additives in the same way as described in Examples 3-5 and 7-10.
Granulate and tablets containing EPA/DHA can be prepared from marine oils optionally with additives in the same way as described in Examples 6-10.

Claims

Claims
1. Granulate comprising
(i) an oil-powder mixture containing 2-75-% (w/w) vegetable oil and/or marine o , wherein the essential fatty acids are selected from gamma-linolenic acid (GLA), eicosapentaenoic acid (EPA) and/or docosahexanenoic acid (DHA), and/or other marine oils and a water-soluble carrier in combination with
(ii) a solid, pulverulent filler and
(iii) a binder.
2. Granulate comprising
(i) an oil-powder mixture containing 2-75 % (w/w) vegetable oil and/or marine oil, wherein the essential fatty acids are selected from gamma-linolenic acid (GLA), eicosapentaenoic acid (EPA) and/or docosahexanenoic acid (DHA), and/or other marine oils and a water-soluble carrier, in combination with
(ii) a solid, pulverulent filler and
(iii) a binder, said granulate is obtainable by
a) dry-mixing the oil-powder mixture optionally containing an antioxidant with the solid, pulverulent filler and optionally adding a diluent etc.,
b) dissolving a binder in water,
c) mixing the dry-mixture (a) and the dissolved binder (b) with vigorous stirring, to obtain a granulate,
d) drying the granulate obtained and e) driven the dried granulate, optionally together with additives to desired size.
3. Granulate according to claims 1 or 2 wherein the oil-powder mixture containing 40 to 75 % (w/w) oil.
4. Granulate according to any of claims 1-3 wherein the oil-powder mixture containing 50 % (w/w) oil.
5. Granulate according to any of claims 1-4. wherein the oil is borage oil, cod liver oil or shark liver oil.
6. Granulate according to any of claims 1-5 wherein the water-soluble carrier is soybean protein.
7. Granulate according to any of claims 1 or 2 wherein the filler is a sugar or a modified sugar e.g. dextrose.
8. Granulate according to any of claims 1.or 2 wherein the binder is a polysaccharide or modified polysaccharide e.g. methyl cellulose, hydroxy propyl starch.
9. Granulate comprising an oil-powder mixture containing 50 % (w/w) borage oil and soybean protein in combination with dextrose and methyl cellulose or hydroxy propyl starch.
10. Granulate according to any of claims 1-9 containing an additive such as vitamins, minerals, antibiotics, hormones, cortisones, pollen products and ginseng products.
11. A method for manufacturing
(i) a granulate comprising an oil-powder mixture containing 2-75 % (w/w) vegetable oil and/or marine oil, wherein the essential fatty acids are selected from gamma-linolenic acid (GLA), eicosapentaenoic acid (EPA) and/or docosahexanenoic acid (DHA), and/or other marine oils and a water-soluble carrier, in combination with (ii) a solid, pulverulent filler and
(iii) a binder characterized by
a) dry-mixing the oil-powder mixture optionally containing an antioxidant with the solid, pulverulent filler and optionally adding a diluent, etc.,
b) dissolving a binder in water,
c) mixing the dry-mixture (a) and the dissolved binder (b) with vigorous stirring, to obtain a granulate
d) drying the granulate obtained and
e) driven the dried granulate optionally together with additives to desired size.
12. Use of a granulate according to any of claims 1-10 in dietary supplement products, in food products fodder or in pharmaceutical products.
13. Use of a granulate according to any of claims 1-10 for the manufacture of tablets.
14. Tablet comprising a granulate according to any of claims 1-10 in combination with a binder.
15. Tablet according to claim 14 containing an acid/bicarbonate mixture.
16. Tablet according to any of claims 14-15 containing additives such as vitamins, minerals, antibiotics, enzymes, hormones, cortisones, pollen products and ginseng products.
17. Tablet according to claim 16 wherein the additive is vitamin B6.
18. Tablet according to claim 16 wherein the additive is physiologically assimilable selenium.
19. Tablet according to claim 16 wherein the additive is lecithin and pollen products.
20. Use of a tablet according to any of claims 14-19 as a pharmaceutical product or as a dietary supplement product.
EP87906285A 1986-09-29 1987-09-18 A granulate containing gamma linolenic acid, eicosapentaenoic acid and/or docosahexaenoic acid, the method for its manufacturing, its use in edible products, and a tablet containing it Pending EP0324762A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8604117 1986-09-29
SE8604117A SE8604117D0 (en) 1986-09-29 1986-09-29 COMPOSITION

Publications (1)

Publication Number Publication Date
EP0324762A1 true EP0324762A1 (en) 1989-07-26

Family

ID=20365745

Family Applications (2)

Application Number Title Priority Date Filing Date
EP87850283A Withdrawn EP0266323A1 (en) 1986-09-29 1987-09-18 Tablet containing gamma-linolenic acid, eicosa pentaenoic acid and/or docosahexaenoic acid, and method for its manufacturing
EP87906285A Pending EP0324762A1 (en) 1986-09-29 1987-09-18 A granulate containing gamma linolenic acid, eicosapentaenoic acid and/or docosahexaenoic acid, the method for its manufacturing, its use in edible products, and a tablet containing it

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP87850283A Withdrawn EP0266323A1 (en) 1986-09-29 1987-09-18 Tablet containing gamma-linolenic acid, eicosa pentaenoic acid and/or docosahexaenoic acid, and method for its manufacturing

Country Status (6)

Country Link
EP (2) EP0266323A1 (en)
AU (1) AU8028287A (en)
DK (1) DK291988A (en)
FI (1) FI891478A0 (en)
SE (1) SE8604117D0 (en)
WO (1) WO1988002221A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8718523D0 (en) * 1987-08-05 1987-09-09 Unilever Plc Marine/vegetable oil blend
GB2223943A (en) * 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
DE3901048A1 (en) * 1989-01-14 1990-07-19 Chimicasa Gmbh ANTIKACHECTIKUM
JPH04502404A (en) * 1989-10-23 1992-05-07 ユニリーバー・ナームローゼ・ベンノートシャープ Dry solid composition containing lipids
GB8923833D0 (en) * 1989-10-23 1989-12-13 Unilever Plc Dry solid compositions containing lipid
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition
GB9026648D0 (en) * 1990-12-07 1991-01-23 Efamol Holdings Nutrition
EP1787532A3 (en) * 1991-01-24 2010-03-31 Martek Biosciences Corporation Microbial oil mixtures and uses thereof
GB9111900D0 (en) * 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JP2558050B2 (en) * 1993-02-18 1996-11-27 イセ食品株式会社 Chicken feed
CA2147109A1 (en) * 1994-04-18 1995-10-19 Gregory A. Reinhart Pet food product containing omega-6 and omega-3 fatty acids and process for reducing inflammatory skin responses
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
GB9419345D0 (en) * 1994-09-26 1994-11-09 Sandoz Nutrition Ltd Organic compounds
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
FR2737849B1 (en) * 1995-08-18 1997-09-19 Boiron ABSORBABLE NUTRITIONAL SUPPLEMENT FOR SENIORS 'DAILY BALANCE
DK2260716T3 (en) * 1996-03-26 2014-05-12 Dsm Ip Assets Bv Late addition of PUFA in manufacturing process for formulation for infants
US6428832B2 (en) * 1996-03-26 2002-08-06 Dsm N.V. Late addition of PUFA in infant formula preparation process
US6048557A (en) * 1996-03-26 2000-04-11 Dsm N.V. PUFA coated solid carrier particles for foodstuff
DK0893953T3 (en) * 1996-03-26 2002-08-26 Dsm Nv PUFA Coated Solid Carriers for Food
EP0923312A1 (en) * 1996-04-29 1999-06-23 K.U. Leuven Research & Development Oral delivery form having a high absorption efficiency and method for making same
DE69728206T2 (en) * 1996-05-14 2005-03-10 Dsm Ip Assets B.V. Production process for carotenoid compositions
JP2002534455A (en) * 1999-01-12 2002-10-15 メルク シャープ エンド ドーム リミテッド Spheroidizing self-emulsifying system for hydrophobic and water sensitive substances
GB9925997D0 (en) * 1999-11-04 2000-01-12 Vitaflo Limited A medical composition for the treatment and/or prevention of malnutrition
DK1155620T3 (en) * 2000-05-18 2005-12-05 Mega Healthcare As Q Dietary supplement with vitamins, minerals and polyunsaturated fatty acids
GB0110408D0 (en) * 2001-04-27 2001-06-20 Smithkline Beecham Plc Composition
FI114894B (en) * 2002-05-02 2005-01-31 Omecol Finland Oy food Composition
FR2839887A1 (en) * 2002-05-22 2003-11-28 Synergia Neutraceutical or pharmaceutical compositions, useful for treating or preventing cardiovascular disease and atheromatous conditions, comprise alpha-linolenic acid and fatty acids having 5- and 6-double bonds
WO2003102072A1 (en) * 2002-05-30 2003-12-11 Granate Seed Limited Starch products involving a starch-lipid complex, their preparation and uses
US8617617B2 (en) * 2002-12-10 2013-12-31 Everett Laboratories, Inc. Methods and kits for co-administration of nutritional supplements
EP1616486A1 (en) * 2004-07-13 2006-01-18 Friesland Brands B.V. Powdered compositions containing an edible oil and their use in food products
US20080279935A1 (en) * 2005-02-18 2008-11-13 Swg Invest As Composition Comprising a Powder Containing Microencapsulated Polyunsaturated Long-Chain Esterified Fatty Acids Distributed in an Effervescent Base
FR2882656B1 (en) * 2005-03-07 2007-06-22 Schwartz Laboratoires Robert S ANTITABAGIC COMPOSITION
EP1969952A1 (en) * 2007-03-07 2008-09-17 Friesland Brands B.V. Allergen-free or dairy free LCPUFA powdered compositions and the use thereof in food products and especially infant formulas
US20140018558A1 (en) 2011-04-28 2014-01-16 Nandakishore Jeevanrao Duragkar Docosahexaenoic acid (dha) as polyunsaturated free fatty acid in its directly compressible powder form and method of isolation thereof
ES2778084A1 (en) * 2019-02-07 2020-08-07 Casanueva Antonio Castano COMPOSITION OF FAT-RICH COMPACT PLUGS OR PELLETS AND THE PROCEDURE FOR THE MANUFACTURE OF THEM WITHOUT STEAM, USING THE KERATINIZING PROPERTIES OF THE SEAFOOD SHELL AS BINDER (Machine-translation by Google Translate, not legally binding)
US12048681B2 (en) 2021-08-09 2024-07-30 Kentucky Equine Research, Inc. Compositions and methods for modulating equine fatty acid profiles
IL314467A (en) * 2022-01-26 2024-09-01 Amarin Pharmaceuticals Ie Ltd Lymph-releasing compositions of fatty acids and uses thereof for lymphatic incorporation and systemic disease treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1580444A (en) * 1976-11-04 1980-12-03 Bio Oil Res Pharmaceutical compositions
US4242364A (en) * 1978-12-19 1980-12-30 R.G.B. Laboratories, Inc. Dry powdered non-dairy food composition containing liquid fat
DE3368377D1 (en) * 1982-04-16 1987-01-29 Nestle Sa Lipid composition for oral, enteral or parenteral feeding
FR2547829B1 (en) * 1983-05-28 1988-11-18 Sekimoto Hiroshi COMPOSITIONS CONTAINING UNSATURATED FATTY ACID COMPOUNDS AND METHOD FOR STABILIZING SUCH COMPOUNDS
EP0175468A3 (en) * 1984-08-10 1987-07-22 Sentrachem Limited Eicosanoids for use in cancer therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8802221A1 *

Also Published As

Publication number Publication date
WO1988002221A1 (en) 1988-04-07
EP0266323A1 (en) 1988-05-04
DK291988D0 (en) 1988-05-27
AU8028287A (en) 1988-04-21
DK291988A (en) 1988-05-30
FI891478A (en) 1989-03-28
FI891478A0 (en) 1989-03-28
SE8604117D0 (en) 1986-09-29

Similar Documents

Publication Publication Date Title
EP0324762A1 (en) A granulate containing gamma linolenic acid, eicosapentaenoic acid and/or docosahexaenoic acid, the method for its manufacturing, its use in edible products, and a tablet containing it
JP4842824B2 (en) Coenzyme Q10-containing composition
KR101255874B1 (en) Nanosized carotenoid cyclodextrin complexes
US7867545B2 (en) Homogenous granular solid matrix containing vegetable protein
JP5147239B2 (en) Coenzyme Q10-containing emulsion composition
DE69422465T2 (en) Cation complexed polysaccharides
CN1741748A (en) Pulverulent phytosterol formulations
CN101032683A (en) Xanthin micro-capsule and the preparing method
WO1992013531A1 (en) Nutritional supplement containing vitamin e
US20120156296A1 (en) Antioxidants in fish oil powder and tablets
JP2000026283A (en) Powder composition containing oily composition
JPH1099046A (en) Production of powder composition
JP2004242508A (en) Food containing coenzyme q10 and water-soluble vitamin
WO2007080787A1 (en) Coenzyme q10-containing water-soluble compositions
JP2003169630A (en) Nutritional composition containing coenzyme q10
JP2007131619A (en) Coenzyme q10-containing active composition
JP4156234B2 (en) Soft capsule
JP7080504B2 (en) Curcumin-containing solid preparation for oral ingestion
JP2005139122A (en) Coenzyme q10-containing emulsified product
KR910004482B1 (en) Oral pharmaceutical compositions
JP2007181441A (en) Method for producing composition mixed with coenzyme q10
NO882311L (en) GRANULATE CONTAINING GAMMA LINOLIC ACID, EICOSAPENTAIC ACID AND / OR DOCOSAHEXAIC ACID, PROCEDURE FOR ITS PREPARATION, ITS USE IN EDIBLE PRODUCTS AND A TABLET CONTAINING SAME.
JP2003321352A (en) Composition containing coenzyme q10
JPH0823881A (en) Starch-egg-oil and fat composition and its use
JP2006117626A (en) Method for producing coenzyme q10-blended composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19890317

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

XX Miscellaneous

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 87850283.0/0266323 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 11.10.89.